AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SENS · NASDAQ · Medical - Devices

Senseonics

Develops implantable Eversense systems for long-term glucose monitoring in adults with diabetes.

$9.37

After-hours close+0.05 (+0.54%)

At close$9.32(−0.85%)

Something off on this page? Send us feedback.

Profile

Senseonics Holdings, Inc.SENSHealth Care

Develops and manufactures Eversense 365, an FDA-cleared implantable continuous glucose-monitoring system for adults with diabetes. U.S. sales, marketing, and distribution returned in-house in January 2026, while Ascensia retains non-exclusive rights in specified European territories.

Develops and manufactures the Eversense 365 continuous glucose-monitoring system, an implantable product cleared by the FDA for use in adults with diabetes. The technology evolved from earlier Eversense sensors with shorter approved wear periods.

Senseonics took direct responsibility for U.S. sales, marketing, and distribution in January 2026, supported by its own sales force. Ascensia previously held worldwide distribution rights and now has non-exclusive rights in specified European territories.

Direct commercialization changed the U.S. operating model. The product's permitted U.S. use is defined by FDA clearances, while Ascensia's European distribution scope follows the agreement.

Company facts

CEOTimothy T. Goodnow, PhD

ListedDec 22, 2015

ExchangeNASDAQ

HeadquartersGermantown, MD

CountryUnited States

Employees137

CIK0001616543

ISINUS81727U3032

Key statistics

Market cap$389.9M

EPS (ttm)−$2.27

P/E (ttm)−4.11

ROE-165.8%

P/B5.98

P/S8.03

Dividend yield—

Beta2.29vs XLV 0.69

Year to date +58.2% · Average volume (30d) 690.9K

Analysts

Price target, next 12 months$14.00+50.1%Median of 17 analysts · vs the Aug 28 close

ConsensusBuy9 of 17 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $9.33

High$18.00+92.9%

Median$14.00+50.1%

Low$8.00−14.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior target	Target
Jul 15, 2026	Mizuho Securities	Target		$18
May 12, 2026	H.C. Wainwright	Target	$1.10	$14
May 11, 2026	Stifel Nicolaus	Target	$9	$8
Mar 3, 2026	Stifel Nicolaus	Target		$9

Earnings

EPS

Estimate−$0.52

ReportedDue Nov 4, 2026

Revenue

Estimate$16.2M

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	−$0.61	−$0.63	−2.8%	$13.4M	$14.5M	+8.6%	+36.31%
May 7, 2026Q1 FY26	−$0.69	−$0.71	−3.6%	$9.8M	$11.7M	+19.1%	−6.16%
Mar 2, 2026Q4 FY25	−$0.43	−$0.46	−7.0%	$14.2M	$14.3M	+0.4%	−18.01%
Nov 5, 2025Q3 FY25	−$0.33	−$0.43	−30.3%	$8.0M	$8.1M	+1.3%	−7.58%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$6.3M	$6.6M	$8.1M	$14.3M	$11.7M	$14.5M
Gross profit	$1.5M	$3.1M	$3.5M	$7.7M	$6.9M	$8.6M
Operating income	−$13.5M	−$14.3M	−$19.6M	−$20.9M	−$31.8M	−$36.0M
Net income	−$14.3M	−$14.5M	−$19.5M	−$20.8M	−$32.3M	−$36.7M
Diluted EPS	−$0.40	−$0.52	−$0.43	−$0.50	−$0.71	−$0.63
Gross margin	24.1%	46.9%	42.8%	53.8%	59.3%	59.1%
Operating margin	-215.6%	-215.4%	-242.1%	-146.8%	-271.9%	-248.5%

Fiscal years (4-quarter sums)FY21 $13.7M · FY22 $16.4M · FY23 $22.4M · FY24 $22.5M · FY25 $35.3M

Revenue by geography · Q2 FY26

United States$12.6M · 87%

Non-US$1.9M · 13%

Balance sheet, Jun 30, 2026Cash & short-term investments $142.7M · Total debt $61.8M · Total assets $176.8M · Shareholders' equity $90.3M

Dividends

No dividends on record.

Ownership

Institutions 20.97%8.76M sharesInsiders 7.25%3.03M sharesOther 71.78%30.00M shares

Shares outstanding 41.79M · Float 38.47M · 92.1% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Sessa Capital IM, L.P.	12.44M	9.90%	13G	Aug 14, 2026
BlackRock, Inc.	2.76M	6.60%	13G	Jul 30, 2026
Vanguard Capital Management LLC	1.62M	3.87%	13F	May 15, 2026
Timothy T. Goodnow · director, officer: President and CEO	1.14M	2.74%	Form 4	Jun 17, 2026
Millennium Management LLC	560.4K	1.34%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 19, 2026	Douglas A. Roeder	director	+13,953	$8.98
May 12, 2026	Douglas A. Roeder	director	+22,686	$5.56
Mar 13, 2026	Timothy T. Goodnow	director, officer: President and CEO	+17,225	$5.79
Mar 13, 2026	Douglas A. Roeder	director	+17,500	$5.73
Nov 10, 2025	Edelman Steven	director	+10,000	$6.55